Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Andros Pharmaceuticals CoROCO:6917 -0.48%40 Net Debt Paydown Yield % is 0.29% as of Jul. 31, 2026, which is 36% below its 10-year median of 0.45. GuruFocus rates ROCO:6917 with a GF Score™ of 40/100 and a GF Value™ of NT$165.96 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,161 Biotechnology companies, Andros Pharmaceuticals Co ranks better than 62.53% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Andros Pharmaceuticals Co's Net Debt Paydown Yield % was 0.29%.
Andros Pharmaceuticals Co (ROCO:6917) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Andros Pharmaceuticals Co Net Debt Paydown Yield % Related Terms
Andros Pharmaceuticals Co Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Andros Pharmaceuticals Co's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Andros Pharmaceuticals Co Net Debt Paydown Yield % Chart
ROCO:6917 vs VRTX, REGN, RVMD: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Andros Pharmaceuticals Co's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Andros Pharmaceuticals Co Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Andros Pharmaceuticals Co's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.29% mean?
Andros Pharmaceuticals Co (ROCO:6917) has a Net Debt Paydown Yield % of 0.29% as of Jul. 31, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Andros Pharmaceuticals Co and its competitors. This is 36% below median its historical median of 0.45. Over the past decade, Andros Pharmaceuticals Co's Net Debt Paydown Yield % has ranged from 0.28 to 0.66. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #435 out of 1161 companies in the Biotechnology industry, placing it in the top 37.5%.
Is Andros Pharmaceuticals Co's Net Debt Paydown Yield % too high?
Andros Pharmaceuticals Co's current Net Debt Paydown Yield % of 0.29% is 36% below median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 0.66. The Biotechnology industry median Net Debt Paydown Yield % is 0.04. Andros Pharmaceuticals Co's value of 0.29% is 625% above this industry median. Based on the distribution chart, Andros Pharmaceuticals Co ranks #435 out of 1161 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Andros Pharmaceuticals Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Net Debt Paydown Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #435 out of 1161 companies for Net Debt Paydown Yield %. This puts Andros Pharmaceuticals Co in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.04. Andros Pharmaceuticals Co's value of 0.29% is 625% above this benchmark. Historically, Andros Pharmaceuticals Co's own Net Debt Paydown Yield % has ranged from 0.28 to 0.66 over the past decade. While the company's 10-year median is 0.45 vs. the industry median of 0.04, Andros Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.04, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Andros Pharmaceuticals Co's current Net Debt Paydown Yield % of 0.29% is 625% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Andros Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Andros Pharmaceuticals Co's current Net Debt Paydown Yield % is 0.29%, which is 36% below median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.96, compared to a current price of NT$30.90 — trading 81.4% below its estimated fair value. The current Net Debt Paydown Yield % is 0.29%, which is 36% below median its 10-year median of 0.45 and 625% above the Biotechnology industry median of 0.04. Andros Pharmaceuticals Co's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Net Debt Paydown Yield % is 0.29% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$30.90 is trading 81.4% below its estimated GF Value™ of NT$165.96.
GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for ROCO:6917:
Net Debt Paydown Yield %: 0.29% (36% below median its 10-year median of 0.45)
GF Value™: NT$165.96 vs. price of NT$30.90 (81.4% below fair value)
Industry Position: 625% above the Biotechnology median (#435 of 1161)
No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
40GF Score
Get the complete analysis for ROCO:6917
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6917 has been successfully added to your 
